study comparing the effects of Esomeprazole adminstered orally and intravenously on basal and pentrigastrin-stimulated acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD)
Study identifier:D9615C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, randomised two way crossover study comparing the effects of 40mg of Esomeprazole adminstered orally and intravenously as a 3 minute injection on basal and pentrigastrin-stimulated acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD)
Medical condition
Gastroesophageal reflux disease (GERD)
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole
Sex
All
Actual Enrollment
60
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Nov 2002
Study Completion Date: 01 Nov 2002
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 IV Nexium | Drug: Esomeprazole 40mg Intravenous infusion over 3 minutes Other Name: Nexium |
| Experimental: 2 Oral Nexium | Drug: Esomeprazole 40mg Oral Other Name: Nexium |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
